Annovis Bio reaches full enrollment in Phase 3 early Alzheimer’s trial of buntanetap

Annovis Bio Inc

Annovis Bio Inc

ANVS

0.00
  • Annovis Bio reached full enrollment of 850 patients in its pivotal Phase 3 trial of buntanetap for early Alzheimer’s disease.
  • Trial targets two top-line readouts: 6-month symptomatic data in Q1 2027, 18-month disease-modifying data in Q1 2028.
  • Company plans two separate FDA NDA submissions, timed shortly after each respective readout.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607070700PRIMZONEFULLFEED9757893) on July 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.